News
RIGL
40.28
+0.26%
0.11
Weekly Report: what happened at RIGL last week (0803-0807)?
Weekly Report · 9h ago
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Kymera Therapeutics (KYMR) and Rigel (RIGL)
TipRanks · 4d ago
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts
Simply Wall St · 4d ago
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Seeking Alpha · 4d ago
Rigel Pharmaceuticals Balances Growth with Rising Costs
TipRanks · 4d ago
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Seeking Alpha · 5d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 5d ago
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
NASDAQ · 5d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 5d ago
Rigel Pharmaceuticals raises FY26 revenue view to $285M-$295M from $275M-$290M
TipRanks · 5d ago
Rigel Pharmaceuticals reports Q2 EPS 88c, consensus (8c)
TipRanks · 5d ago
*Rigel Pharmaceuticals 2Q Rev $78.7M >RIGL
Dow Jones · 5d ago
*Rigel Pharmaceuticals 2Q EPS 88c >RIGL
Dow Jones · 5d ago
*Rigel Pharmaceuticals 2Q Net $17.3M >RIGL
Dow Jones · 5d ago
Here are the major earnings after the close Tuesday
Seeking Alpha · 6d ago
Weekly Report: what happened at RIGL last week (0727-0731)?
Weekly Report · 08/03 10:16
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
PR Newswire · 07/28 12:05
Top profitable small caps trading at bargain P/E multiples during Q2 earnings
Seeking Alpha · 07/27 13:09
Weekly Report: what happened at RIGL last week (0720-0724)?
Weekly Report · 07/27 10:21
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.